RO 5469754
Alternative Names: RO-5469754Latest Information Update: 19 May 2016
At a glance
- Originator Roche
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 19 May 2016 No recent reports of development identified - Phase-I for Undefined indication in Netherlands (SC & IV)
- 01 Nov 2012 Roche completes a phase I trial in Healthy volunteers in Netherlands (NCT01620931)
- 15 Jun 2012 Roche completes enrolment in its phase I trial in Healthy volunteers in Netherlands (NCT01620931)